- Home
- GNPX vs ELAB Comparison
GNPX vs ELAB Comparison
Compare GNPX & ELAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNPX
- ELAB
- Stock Information
- Founded
- GNPX 2009
- ELAB 2020
- Country
- GNPX United States
- ELAB United States
- Employees
- GNPX N/A
- ELAB N/A
- Industry
- GNPX Biotechnology: Pharmaceutical Preparations
- ELAB
- Sector
- GNPX Health Care
- ELAB
- Exchange
- GNPX Nasdaq
- ELAB Nasdaq
- Market Cap
- GNPX 6.6M
- ELAB 6.6M
- IPO Year
- GNPX 2018
- ELAB 2023
- Fundamental
- Price
- GNPX $0.23
- ELAB $2.16
- Analyst Decision
- GNPX
- ELAB
- Analyst Count
- GNPX 0
- ELAB 0
- Target Price
- GNPX N/A
- ELAB N/A
- AVG Volume (30 Days)
- GNPX 3.6M
- ELAB 1.5M
- Earning Date
- GNPX 08-08-2025
- ELAB 08-13-2025
- Dividend Yield
- GNPX N/A
- ELAB N/A
- EPS Growth
- GNPX N/A
- ELAB N/A
- EPS
- GNPX N/A
- ELAB N/A
- Revenue
- GNPX N/A
- ELAB N/A
- Revenue This Year
- GNPX N/A
- ELAB N/A
- Revenue Next Year
- GNPX N/A
- ELAB N/A
- P/E Ratio
- GNPX N/A
- ELAB N/A
- Revenue Growth
- GNPX N/A
- ELAB N/A
- 52 Week Low
- GNPX $0.20
- ELAB $1.95
- 52 Week High
- GNPX $3.97
- ELAB $840.00
- Technical
- Relative Strength Index (RSI)
- GNPX 40.22
- ELAB 45.40
- Support Level
- GNPX $0.22
- ELAB $1.96
- Resistance Level
- GNPX $0.32
- ELAB $2.26
- Average True Range (ATR)
- GNPX 0.03
- ELAB 0.22
- MACD
- GNPX -0.01
- ELAB 0.03
- Stochastic Oscillator
- GNPX 22.07
- ELAB 17.95
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
About ELAB Elevai Labs Inc.
PMGC Holdings Inc advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.